IceCure Medical Ltd. reported first-half 2026 financial results showing a 45% year-over-year revenue increase to $1,818 thousand, driven by growth in system and disposable probe sales. Gross profit rose to $548 thousand from $349 thousand in the prior period. The company incurred a net loss of $8,775 thousand, with operating expenses increasing due to payroll, clinical trials for the CHoICE study, and foreign exchange impacts on NIS-denominated costs. Cash and cash equivalents stood at $12,034 thousand as of June 30, 2026, bolstered by approximately $8.5 million in gross proceeds from equity financings completed during the quarter, including a March registered direct offering and a June private placement. The filing also discloses that on June 4, 2026, the company effected a 1-for-30 reverse stock split. IceCure Medical Ltd. is a medical device company specializing in minimally invasive cryoablation technology for tumor destruction.
